MS6105 is the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. MS6105 Potently degraded LDHA in a time- and ubiquitin-proteasome system dependent manner. MS6105 was significantly more potent than the parent LDH inhibitor in suppressing the growth of both quasi-mesenchymal state and epithelial state pancreatic cancer cell lines. Furthermore, MS6105 was bioavailable in mice through intraperitoneal injection.
MedKoo Cat#: 122438
Name: MS6105
CAS#: N/A
Chemical Formula: C65H81N9O9S3
Exact Mass: 1227.5319
Molecular Weight: 1228.60
Elemental Analysis: C, 63.55; H, 6.65; N, 10.26; O, 11.72; S, 7.83
The following data is based on the product molecular weight 1,228.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
